Clinical Trial

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Study acronym: RAPID-01
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-14; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2024-09-02
Trial Details
NCT Number NCT06138990
Lead Sponsor ETH Zurich
Collaborators: University of Zurich, Insel Gruppe AG, University Hospital Bern
Conditions AML, Adult
Enrollment 88 participants
Start Date 2024-09-02
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-16